Chart Review Study to Describe the Clinical Profile of Idiopathic Pulmonary Fibrosis (IPF) Patients Treated With Nintedanib (OFEV®) in Real-world Practice in Spain

NCT03281200 · clinicaltrials.gov ↗

COMPLETED

Status

172

Enrollment

INDUSTRY

Sponsor class

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

DRUG: L - Antineoplastic and immunomodulating agents
DRUG: L01 - Antineoplastic agents
DRUG: L01X - Other antineoplastic agents
DRUG: L01XE - Protein kinase inhibitors
DRUG: L01XE31 - Nintedanib

Sponsor

Boehringer Ingelheim